Is Tirzepatide FDA Approved? Not When Compounded

Is tirzepatide FDA approved? Not in every form. Mounjaro is FDA-approved; compounded tirzepatide is not. Mounjaro received its original authorization for adults with type 2 diabetes in May 2022. Zepbound is FDA-approved; compounded tirzepatide is not. Zepbound followed for chronic weight management in November 2023 and for moderate-to-severe obstructive sleep apnea in adults with obesity in December 2024.

Those authorizations attach to named products, manufacturers, labels and uses. They do not attach to every preparation containing the same active ingredient. That distinction is the answer behind most confusion about tirzepatide brand names and compounded medication.

Is tirzepatide FDA approved? Not when compounded

The short answer is easiest to see as a product timeline:

The dates and uses come from the FDA's Mounjaro trial snapshot, Zepbound authorization letter, and December 2024 sleep-apnea announcement. The agency's January 2026 Zepbound label still lists the two adult uses: long-term weight reduction and moderate-to-severe sleep apnea in adults with obesity. For the naming details, see tirzepatide brand names.

What FDA approval does not cover

Regulatory authorization belongs to the finished drug product, not to tirzepatide as an abstract molecule. The submitted formulation, manufacturing controls, delivery system, indication and label are reviewed together. A compounder prepares a different product under a different legal framework. It is not a generic Mounjaro or Zepbound.

The clinical record helps explain the branded uses. In SURPASS-1, a 40-week randomized trial published in The Lancet in 2021, tirzepatide reduced mean HbA1c by 1.87 to 2.07 percentage points across the three dose groups, versus a 0.04-point increase with placebo (Rosenstock et al., PMID 34186022). In SURMOUNT-1, published in The New England Journal of Medicine in 2022, mean weight change at 72 weeks ranged from −15.0% to −20.9% across tirzepatide groups, versus −3.1% with placebo (Jastreboff et al., PMID 35658024).

For sleep apnea, the two SURMOUNT-OSA trials published in The New England Journal of Medicine in 2024 found estimated treatment differences in apnea-hypopnea index of −20.0 and −23.8 events per hour versus placebo at 52 weeks (Malhotra et al., PMID 38912654). Trial results support a label; they do not transfer that label to a compounded preparation.

Why the shortage changed tirzepatide compounding

Tirzepatide injection entered the federal shortage list in December 2022. While a listed drug is in shortage, sections 503A and 503B provide pathways for compounders that meet their respective conditions to prepare versions that would otherwise run into restrictions on making copies of available approved drugs.

The FDA first declared the shortage resolved in October 2024, reconsidered after litigation, and confirmed the decision on December 19, 2024. Its tirzepatide compounding timeline gave 503A pharmacies a transition period that ultimately ended after a court ruling on March 5, 2025; the 503B transition ended March 19, 2025. These dates ended shortage-based enforcement discretion. They did not convert compounded preparations into branded products.

On August 27, 2026, the Fifth Circuit affirmed the district court's judgment, holding that the FDA's shortage determination was not arbitrary or capricious. That ruling left the resolved-shortage decision in place.

Semaglutide is a different GLP-1 medicine with its own brands, labels and shortage history. Its regulatory status cannot be used as a shortcut for tirzepatide, but it is a related option a provider may assess on its own facts.

What 503A and 503B mean after the shortage

The two sections are not interchangeable. Under 503A, a state-licensed pharmacy or physician compounds for an identified patient after receiving a prescription. FDA's April 2026 summary says a preparation with the same active ingredient, similar strength and same route is generally considered essentially a copy. The exception is patient-specific: the prescriber determines and documents that a change produces a significant difference for that identified patient. A different formulation by itself is not enough; the documented clinical difference matters.

Section 503B governs registered outsourcing facilities and can allow distribution without first receiving a patient-specific prescription, but it has separate copy and bulk-substance restrictions. In April 2026, FDA said tirzepatide was neither on the shortage list nor the 503B bulks list. The agency also proposed excluding tirzepatide from the 503B bulks list; the announcement described that step as a proposal and said comments would inform a final determination.

This is why the resolved shortage is not a one-word answer to whether an individual compounded prescription fits federal conditions. A licensed provider may still prescribe a patient-specific compounded formulation when they determine it is clinically appropriate and the legal conditions are met; that decision belongs to the patient and prescriber. How compounded medications are made explains the pharmacy process, while compounded tirzepatide covers the product distinction in more detail.

What the status means before a prescription

Branded and compounded routes should be discussed as different products, not as interchangeable packaging. The useful questions are which indication applies, why a particular formulation is being considered, what the prescription documents, and which pharmacy will dispense it. Approval status is one fact in that conversation, not a marketing verdict.

Through Promise, tirzepatide is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. A licensed provider reviews every request and not everyone qualifies. If a provider does prescribe, the clinical and regulatory reasoning should be specific to that patient rather than borrowed from the brand label.